Adjuvant Global Health Technology Fund, L.P. Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$2.5M
Insider Sells Quantity
10
Insider Sells Sum
$3.98M

Insider Activity of Adjuvant Global Health Technology Fund, L.P.

The largest purchase of all time was on 2022-03-29 and amounted to 166666 shares of AN2 Therapeutics, Inc. for $2.5M.

The largest sale of all time was on 2024-01-16 and amounted to 100000 shares of AN2 Therapeutics, Inc. for $1.97M.

Biography of Adjuvant Global Health Technology Fund, L.P.

No biography is available at this moment.

2024-01-16SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
100,000
3.9381%
$19.65$1.97M-89.74%
2023-11-14SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
1,810
0.0586%
$16.15$29,224-84.06%
2023-10-02SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
5,672
0.1827%
$16.07$91,149-80.98%
2023-09-29SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
99,101
3.2333%
$16.28$1.61M-81.53%
2023-09-28SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
8,516
0.2749%
$16.11$137,193-81.33%
2023-09-27SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
841
0.0271%
$16.07$13,515-81.17%
2023-09-13SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
400
0.0128%
$16.00$6,400-79.54%
2023-09-07SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
3,378
0.1087%
$16.05$54,217-79.87%
2023-09-06SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
3,762
0.1208%
$16.02$60,267-80.19%
2023-08-23SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
400
0.0128%
$16.00$6,400-77.74%
2022-03-29PurchaseAN2 Therapeutics, Inc.
ANTX
10 percent owner
166,666
5.0102%
$15.00$2.5M-24.72%
Total: 11
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.